Prognostic Factors of Extramammary Paget’s Disease

  • Naohito HattaEmail author
Skin Cancer (T Ito, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Skin Cancer

Opinion statement

Most patients with extramammary Paget’s disease (EMPD) show a good prognosis; however, some patients develop fatal metastases. Early detection is important for improving prognosis, due to the difficulties associated with the treatment of distant EMPD metastases. Several studies have emphasized the importance of the invasion level of the primary lesion for predicting the presence of metastasis, and deeper invasion or increased thickness is correlated with poorer prognosis. Vascular tumor invasion of the primary lesion can also predict the risk of metastasis. Lymph node metastasis is a strong indicator for poor prognosis, and the number of lymph node metastases affects patient outcome, in that there is a significant difference in survival between patients with zero or one lymph node metastasis and those with more than two lymph node metastases. Serum markers may be able to predict the presence of systemic metastases, and carcinoembryonic antigen and cytokeratin 19 fragment 21-1 reflect disease progression and may be clinically valuable. Although several genetic alterations have been determined for EMPD, factors determining prognosis should be further explored.


Invasion Genitalia Lymph node Metastasis Serum marker 


Compliance with Ethical Standards

Conflict of Interest

The author declares that he has no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Lam C, Funaro D. Extramammary Paget’s disease: summary of current knowledge. Dermatol Clin. 2010;28:807–26.CrossRefPubMedGoogle Scholar
  2. 2.
    Pierie JP, Choudry U, Muzikansky A, Finkelstein DM, Ott MJ. Prognosis and management of extramammary Paget’s disease and the association with secondary malignancies. J Am Coll Surg. 2003;196:45–50.CrossRefPubMedGoogle Scholar
  3. 3.
    •• Ohara K, Fujisawa Y, Yoshino K, Kiyohara Y, Kadono T, Murata Y, et al. A proposal for a TNM staging system for extramammary Paget disease: retrospective analysis of 301 patients with invasive primary tumors. J Dermatol Sci. 2016;83:234–9. Important proposal of TNM staging system.Google Scholar
  4. 4.
    Hatta N, Yamada M, Hirano T, Fujimoto A, Morita R. Extramammary Paget’s disease: treatment, prognostic factors and outcome in 76 patients. Br J Dermatol. 2008;158:313–8.PubMedGoogle Scholar
  5. 5.
    Ito Y, Igawa S, Ohishi Y, Uehara J, Yamamoto AI, Iizuka H. Prognostic indicators in 35 patients with extramammary Paget’s disease. Dermatol Surg. 2012;38:1938–44.CrossRefPubMedGoogle Scholar
  6. 6.
    •• Ito T, Kaku Y, Nagae K, Nakano-Nakamura M, Nakahara T, Oda Y, et al. Tumor thickness as a prognostic factor in extramammary Paget’s disease. J Dermatol. 2015;42:269–75. Important trial on prognostic factor in EMPD.Google Scholar
  7. 7.
    Siesling S, Elferink MA, van Dijck JA, Pierie JP, Blokx WA. Epidemiology and treatment of extramammary Paget disease in the Netherlands. Eur J Surg Oncol. 2007;33:951–5.CrossRefPubMedGoogle Scholar
  8. 8.
    Karam A, Dorigo O. Treatment outcomes in a large cohort of patients with invasive Extramammary Paget’s disease. Gynecol Oncol. 2012;125:346–51.CrossRefPubMedGoogle Scholar
  9. 9.
    Lee SJ, Choe YS, Jung HD, Ahn SK, Cha YC, Cho KH, et al. A multicenter study on extramammary Paget’s disease in Korea. Int J Dermatol. 2011;50:508–15.CrossRefPubMedGoogle Scholar
  10. 10.
    Cheng PS, Lu CL, Cheng CL, Lai FJ. Significant male predisposition in extramammary Paget disease: a nationwide population-based study in Taiwan. Br J Dermatol. 2014;171:191–3.CrossRefPubMedGoogle Scholar
  11. 11.
    • Yao H, Xie M, Fu S, Guo J, Peng Y, Cai Z, et al. Survival analysis of patients with invasive extramammary Paget disease: implications of anatomic sites. BMC Cancer. 2018;18:403. Survival analysis on large number of Patients.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    • Iacoponi S, Zalewski K, Fruscio R, Diaz-De la Noval B, De Iaco P, Ceccaroni M, et al. Prognostic factors for recurrence and survival among patients with invasive vulvar Paget disease included in the VULCAN study. Int J Gynaecol Obstet. 2016;133:76–9. Multicenter study on prognostic factors.Google Scholar
  13. 13.
    McCarter MD, Quan SH, Busam K, Paty PP, Wong D, Guillem JG. Long-term outcome of perianal Paget’s disease. Dis Colon Rectum. 2003;46:612–6.CrossRefPubMedGoogle Scholar
  14. 14.
    Mengjun B, Zheng-Qiang W, Tasleem MM. Extramammary Paget’s disease of the perianal region: a review of the literature emphasizing management. Dermatol Surg. 2013;39:69–75.CrossRefPubMedGoogle Scholar
  15. 15.
    Chanda JJ. Extramammary Paget’s disease: prognosis and relationship to internal malignancy. J Am Acad Dermatol. 1985;13:1009–14.CrossRefPubMedGoogle Scholar
  16. 16.
    Tsutsumida A, Yamamoto Y, Minakawa H, Yoshida T, Kokubu I, Sugihara T. Indications for lymph node dissection in the treatment of extramammary Paget’s disease. Dermatol Surg. 2003;29:21–4.PubMedGoogle Scholar
  17. 17.
    Yoon SN, Park IJ, Kim HC, Yu CS, Lee MW, Koh JK, et al. Extramammary Paget’s disease in Korea: its association with gastrointestinal neoplasms. Int J Color Dis. 2008;23:1125–30.CrossRefGoogle Scholar
  18. 18.
    Kang Z, Xu F, Zhu Y, Fu P, Zhang QA, Hu T, et al. Genetic analysis of mismatch repair genes alterations in extramammary Paget disease. Am J Surg Pathol. 2016;40:1517–25.CrossRefPubMedGoogle Scholar
  19. 19.
    Goldblum JR, Hart WR. Perianal Paget’s disease: a histologic and immunohistochemical study of 11 cases with and without associated rectal adenocarcinoma. Am J Surg Pathol. 1998;22:170–9.CrossRefPubMedGoogle Scholar
  20. 20.
    De Nisi MC, D'Amuri A, Toscano M, Lalinga AV, Pirtoli L, Miracco C. Usefulness of CDX2 in the diagnosis of extramammary Paget disease associated with malignancies of intestinal type. Br J Dermatol. 2005;153:677–9.CrossRefPubMedGoogle Scholar
  21. 21.
    van der Linden M, Schuurman MS, Bulten J, Massuger L, IntHout J, van der Aa MA, et al. Stop routine screening for associated malignancies in cutaneous non-invasive vulvar Paget disease? Br J Dermatol. 2018.Google Scholar
  22. 22.
    Feuer GA, Shevchuk M, Calanog A. Vulvar Paget’s disease: the need to exclude an invasive lesion. Gynecol Oncol. 1990;38:81–9.CrossRefPubMedGoogle Scholar
  23. 23.
    Cohen JM, Granter SR, Werchniak AE. Risk stratification in extramammary Paget disease. Clin Exp Dermatol. 2015;40:473–8.CrossRefPubMedGoogle Scholar
  24. 24.
    Fine BA, Fowler LJ, Valente PT, Gaudet T. Minimally invasive Paget’s disease of the vulva with extensive lymph node metastases. Gynecol Oncol. 1995;57:262–5.CrossRefPubMedGoogle Scholar
  25. 25.
    Shu B, Shen XX, Chen P, Fang XZ, Guo YL, Kong YY. Primary invasive extramammary Paget disease on penoscrotum: a clinicopathological analysis of 41 cases. Hum Pathol. 2016;47:70–7.CrossRefPubMedGoogle Scholar
  26. 26.
    Oji M, Furue M, Tamaki K. Serum carcinoembryonic antigen level in Paget’s disease. Br J Dermatol. 1984;110:211–3.CrossRefPubMedGoogle Scholar
  27. 27.
    Zhu Y, Ye DW, Yao XD, Zhang SL, Dai B, Zhang HL, et al. Clinicopathological characteristics, management and outcome of metastatic penoscrotal extramammary Paget’s disease. Br J Dermatol. 2009;161:577–82.CrossRefPubMedGoogle Scholar
  28. 28.
    Kato J, Sumikawa Y, Hida T, Kamiya T, Horimoto K, Kamiya S, et al. Serum cytokeratin 19 fragment 21-1 is a useful tumor marker for the assessment of extramammary Paget’s disease. J Dermatol. 2017;44:666–70.CrossRefPubMedGoogle Scholar
  29. 29.
    Inoguchi N, Matsumura Y, Kanazawa N, Morita K, Tachibana T, Sakurai T, et al. Expression of prostate-specific antigen and androgen receptor in extramammary Paget’s disease and carcinoma. Clin Exp Dermatol. 2007;32:91–4.PubMedGoogle Scholar
  30. 30.
    Kang Z, Zhang Q, Zhang Q, Li X, Hu T, Xu X, et al. Clinical and pathological characteristics of extramammary Paget’s disease: report of 246 Chinese male patients. Int J Clin Exp Pathol. 2015;8:13233–40.PubMedPubMedCentralGoogle Scholar
  31. 31.
    Battles OE, Page DL, Johnson JE. Cytokeratins, CEA, and mucin histochemistry in the diagnosis and characterization of extramammary Paget’s disease. Am J Clin Pathol. 1997;108:6–12.CrossRefPubMedGoogle Scholar
  32. 32.
    Goldblum JR, Hart WR. Vulvar Paget’s disease: a clinicopathologic and immunohistochemical study of 19 cases. Am J Surg Pathol. 1997;21:1178–87.CrossRefPubMedGoogle Scholar
  33. 33.
    Ohnishi T, Watanabe S. The use of cytokeratins 7 and 20 in the diagnosis of primary and secondary extramammary Paget’s disease. Br J Dermatol. 2000;142:243–7.CrossRefPubMedGoogle Scholar
  34. 34.
    Yoshii N, Kitajima S, Yonezawa S, Matsukita S, Setoyama M, Kanzaki T. Expression of mucin core proteins in extramammary Paget’s disease. Pathol Int. 2002;52:390–9.CrossRefPubMedGoogle Scholar
  35. 35.
    Liegl B, Leibl S, Gogg-Kamerer M, Tessaro B, Horn LC, Moinfar F. Mammary and extramammary Paget’s disease: an immunohistochemical study of 83 cases. Histopathology. 2007;50:439–47.CrossRefPubMedGoogle Scholar
  36. 36.
    Hata H, Abe R, Hoshina D, Saito N, Homma E, Aoyagi S, et al. MUC5AC expression correlates with invasiveness and progression of extramammary Paget’s disease. J Eur Acad Dermatol Venereol. 2014;28:727–32.CrossRefPubMedGoogle Scholar
  37. 37.
    • Fukuda K, Funakoshi T. Metastatic extramammary Paget’s disease: pathogenesis and novel therapeutic approach. Front Oncol. 2018;8:38. Excellent review on treatment of metastatic EMPD.CrossRefPubMedPubMedCentralGoogle Scholar
  38. 38.
    Takata M, Fujimoto A, Aoki H, Hatta N, Ooi A, Takehara K. erbB-2 overexpression but no activation of beta-Catenin gene in extramammary Paget’s disease. J Invest Dermatol. 1999;113:258–62.CrossRefPubMedGoogle Scholar
  39. 39.
    Tanaka R, Sasajima Y, Tsuda H, Namikawa K, Tsutsumida A, Otsuka F, et al. Human epidermal growth factor receptor 2 protein overexpression and gene amplification in extramammary Paget disease. Br J Dermatol. 2013;168:1259–66.CrossRefPubMedGoogle Scholar
  40. 40.
    Aoyagi S, Akiyama M, Shimizu H. High expression of Ki-67 and cyclin D1 in invasive extramammary Paget’s disease. J Dermatol Sci. 2008;50:177–84.CrossRefPubMedGoogle Scholar
  41. 41.
    Liu H, Moroi Y, Yasumoto S, Kokuba H, Imafuku S, Koga T, et al. Expression of insulin-like growth factor-1 receptor, p-AKT and p-ERK1/2 protein in extramammary Paget’s disease. Br J Dermatol. 2006;155:586–91.CrossRefPubMedGoogle Scholar
  42. 42.
    Liu HJ, Moroi Y, Masuda T, Yasumoto S, Kokuba H, Imafuku S, et al. Expression of phosphorylated Stat3, cyclin D1 and Bcl-xL in extramammary Paget disease. Br J Dermatol. 2006;154:926–32.CrossRefPubMedGoogle Scholar
  43. 43.
    Chen S, Moroi Y, Urabe K, Takeuchi S, Kido M, Hayashida S, et al. Differential expression of two new members of the p53 family, p63 and p73, in extramammary Paget's disease. Clin Exp Dermatol. 2008;33:634–40.CrossRefPubMedGoogle Scholar
  44. 44.
    Chen SY, Moroi Y, Urabe K, Takeuchi S, Kido M, Hayashida S, et al. Concordant overexpression of p-FAK and p-ERK1/2 in extramammary Paget’s disease. Arch Dermatol Res. 2008;300:195–201.CrossRefPubMedGoogle Scholar
  45. 45.
    Qian Y, Takeuchi S, Chen SJ, Dugu L, Tsuji G, Xie L, et al. Nerve growth factor, brain-derived neurotrophic factor and their high-affinity receptors are overexpressed in extramammary Paget’s disease. J Cutan Pathol. 2010;37:1150–4.CrossRefPubMedGoogle Scholar
  46. 46.
    Qian Y, Zhang N, Chen S, Chu S, Feng A, Liu H. PI3K, Rac1 and pPAK1 are overexpressed in extramammary Paget’s disease. J Cutan Pathol. 2012;39:1010–5.CrossRefPubMedGoogle Scholar
  47. 47.
    Kang Z, Xu F, Zhang QA, Lin J, Wu Z, Zhang X, et al. Correlation of DLC1 gene methylation with oncogenic PIK3CA mutations in extramammary Paget’s disease. Mod Pathol. 2012;25:1160–8.CrossRefPubMedGoogle Scholar
  48. 48.
    Duttagupta R, Jiang R, Gollub J, Getts RC, Jones KW. Impact of cellular miRNAs on circulating miRNA biomarker signatures. PLoS One. 2011;6:e20769.CrossRefPubMedPubMedCentralGoogle Scholar
  49. 49.
    Guo H, Qi RQ, Lv YN, Wang HX, Hong YX, Zheng S, et al. miR-31 is distinctively overexpressed in primary male extramammary Paget’s disease. Oncotarget. 2016;7:24559–63.Google Scholar
  50. 50.
    Kudo G, Toyama H, Hasegawa K, Kuroda M, Hattori H, Ishiguro M, et al. Sentinel lymph node navigation surgery in Paget’s disease of the vulva. Clin Nucl Med. 2002;27:909–10.CrossRefPubMedGoogle Scholar
  51. 51.
    Hatta N, Morita R, Yamada M, Echigo T, Hirano T, Takehara K, et al. Sentinel lymph node biopsy in patients with extramammary Paget’s disease. Dermatol Surg. 2004;30:1329–34.PubMedGoogle Scholar
  52. 52.
    Ewing T, Sawicki J, Ciaravino G, Rumore GJ. Microinvasive Paget’s disease. Gynecol Oncol. 2004;95:755–8.CrossRefPubMedGoogle Scholar
  53. 53.
    Nakamura Y, Fujisawa Y, Ishikawa M, Nakamura Y, Ishitsuka Y, Maruyama H, et al. Usefulness of sentinel lymph node biopsy for extramammary Paget disease. Br J Dermatol. 2012;167:954–6.CrossRefPubMedGoogle Scholar
  54. 54.
    Ogata D, Kiyohara Y, Yoshikawa S, Tsuchida T. Usefulness of sentinel lymph node biopsy for prognostic prediction in extramammary Paget’s disease. Eur J Dermatol. 2016;26:254–9.PubMedGoogle Scholar
  55. 55.
    • Fujisawa Y, Yoshino K, Kiyohara Y, Kadono T, Murata Y, Uhara H, et al. The role of sentinel lymph node biopsy in the management of invasive extramammary Paget’s disease: multi-center, retrospective study of 151 patients. J Dermatol Sci. 2015;79:38–42. Multicenter trial on sentinel lymph node biopsy in invasive EMPD.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of DermatologyToyama Prefectural Central HospitalToyamaJapan

Personalised recommendations